Analysis of the effectiveness and safety of maintenance treatment with intravenous ustekinumab in inflammatory bowel disease.

Background And Purpose Of The Study: Ustekinumab is a monoclonal antibody approved for the treatment of moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). In spite of being an effective treatment, patients may have suboptimal response, or lose it over time. In these cases, ustekinumab intravenous (IV) maintenance therapy has been explored as a rescue option.

Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study.

Background: Disease-modifying therapies for multiple sclerosis have been developed tremendously over the last two decades.

Objective: The aim of this study was to review the short-, medium-, and long-term safety of alemtuzumab in relapsing remitting multiple sclerosis (RRMS).

Method: This retrospective observational study (2015-2019) included all patients with highly active or rapidly progressing and aggressive RRMS who were treated with alemtuzumab at the Cabueñes University Hospital.